Using C elegant they screened 22000 genes and identified the mitochondrial electron transport chain as a central regulator of age related decline. They found that signals from mildly stressed mitochondria prevent the failure of proteostasis in the cell that comes with age. “This has not been seen before. People have always known that prolonged mitochondrial stress can be deleterious, but we discovered that when you stress mitochondria just a little, the mitochondrial stress signal is interpreted by the cell as a survival strategy. It makes the animals completely stress resistant and doubles their lifespan. It’s like magic.”

Adeona Pharmaceuticals, Inc. (AMEX: AEN) is a pharmaceutical company developing new medicines for serious central nervous systems diseases.  Our primary strategy is to license clinical-stage drug candidates that have already demonstrated a certain level of clinical efficacy and develop them to a valuation inflection point resulting in a significant development and marketing collaboration. We have four drug candidates and one medical food candidate in development.

On March 18, 2014, we completed our initial public offering and since then have been listed on the Nasdaq Capital Market under the symbol “GLMD”.

Park, J. Y. et al. Gomisin J from Schisandra chinensis induces vascular relaxation via activation of endothelial nitric oxide synthase. Vasc Pharmacol. 57, 124–130 (2012).

Approximately 1 × 106 cells were treated with serum-depleted medium (0.1% FBS) for 24 h to synchronize growth. Then cells were incubated in complete culture medium for another 24 h, detached by trypsinization, stored in culture medium and recovered by centrifugation. After fixation with 75% ethanol overnight at 4 °C, cells were digested with DNase-free RNase in PBS containing 5 μg/ml propidium iodide (PI) for DNA staining (30 min at 37 °C). FACS analysis was performed using a BD FACS Calibur flow cytometer equipped with CELL Quest software.

What began as a single case has snowballed into a major risk-assessment puzzle. The European Medicines Agency (EMA) is considering not only valsartan and losartan, but candesartan, irbesartan, and olmesartan in its efforts to find root cause (7). Both FDA and the General European Official Medicines Control Laboratories Network (GEON) published methods

        The patent position of biotechnology and pharmaceutical companies generally is highly uncertain. No consistent policy regarding the breadth of claims allowed in biotechnology and pharmaceutical patents has emerged to date in the U.S. or in any foreign jurisdictions. In addition, the determination of patent rights with respect to pharmaceutical compounds commonly involves complex legal and factual questions, which has in recent years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain.

        (a)   All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Hi I Aldebaran, AD is 2 hot disease with first hit being severe damage to micro vascular system. Second hit is amyloid cascDe with Tau. Late problem is microfilm activation which causes chronic inflammation which causes more damage. Want to lower activity microfilm not increase, but this late stage and will not help. I rate their chance for success less than zero.

Fujitani, M. et al. P311 accelerates nerve regeneration of the axotomized facial nerve. Journal of neurochemistry. 91, 737–744 (2004).

We determined that the transaction price at contract inception was $2.1 million consisting of the upfront, non-refundable payment. None of the clinical or regulatory milestones were included in the transaction price upon inception, as all milestone amounts were fully constrained. Management assessed that the likelihood of occurrence of the other performance obligations in the Samil Agreement was remote upon contract inception. As such, the standalone value of such performance obligations was deemed de minimis and none of the transaction price was allocated to those obligations. Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, and therefore have also been excluded from the transaction price.

        Any consideration related to the sales-based milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the licenses granted to Merck and therefore were excluded from the transaction price.